Metabolic Comorbidity in Severe Mental Illness: Treating the Brain While Minding the Body-Presentation and Q&A

Video Transcription

Video Summary

Dr. Margaret Han, a Clinician Scientist in the Schizophrenia Division at CAMH, discussed the topic of metabolic comorbidity in severe mental illness in a webinar. She highlighted the high rates of cardiovascular disease in individuals with severe mental illness, as well as the role of antipsychotic medications in causing metabolic side effects. Dr. Han discussed various treatment options for managing metabolic comorbidity, including the use of medications such as metformin and GLP-1 receptor agonists. She also emphasized the importance of screening and monitoring metabolic parameters in patients with severe mental illness. Dr. Han addressed questions related to the use of metformin and GLP-1 agonists, as well as the challenges associated with insurance coverage and access to these medications. She also discussed the role of lifestyle interventions and the potential impact of social determinants of health on dietary counseling. The webinar provided valuable insights into the management of metabolic comorbidity in individuals with severe mental illness, and highlighted the need for further research in this area.

Keywords

metabolic comorbidity

severe mental illness

cardiovascular disease

antipsychotic medications

metformin

GLP-1 receptor agonists

screening

monitoring metabolic parameters

insurance coverage

lifestyle interventions